TET2 and pulmonary arterial hypertension: We hypothesized that patients with a TET2 mutation, which occurs in 0.39% of patients with PAH, would manifest a global hypermethylation relative to control subjects or patients with PAH that were not associated with a TET2 mutation (Potus et al. 2020).